Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Frontiers in Oncology
|
June 15, 2026
Glioblastoma, <i>IDH-</i>wildtype, with a novel <i>MEF2D-NTRK1</i> gene fusion: a case report
Anaya Dewey, Joaquina C Baranda, Wei Zhang, et al.
Diagnostic Cytopathology
|
June 4, 2004
Hepatocellular carcinoma diagnosed by fine-needle aspiration of the parotid gland
Maria M Romanas, Rachel Cherian, Douglas H McGregor, et al.
Oncology
|
April 6, 2021
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
Robert L Coleman, J Thaddeus Beck, Joaquina C Baranda, et al.
Cancer
|
April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer Investigation
|
October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Caio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Translational Medicine Communications
|
April 15, 2025
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Joaquina C Baranda, Ghulam Rehman Mohyuddin, Andrés M Bur, et al.
Clinical and Translational Science
|
June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
JCO Oncology Advances
|
February 7, 2025
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Frontiers in Oncology
|
June 15, 2026
Glioblastoma, <i>IDH-</i>wildtype, with a novel <i>MEF2D-NTRK1</i> gene fusion: a case report
Anaya Dewey, Joaquina C Baranda, Wei Zhang, et al.
Diagnostic Cytopathology
|
June 4, 2004
Hepatocellular carcinoma diagnosed by fine-needle aspiration of the parotid gland
Maria M Romanas, Rachel Cherian, Douglas H McGregor, et al.
Oncology
|
April 6, 2021
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
Robert L Coleman, J Thaddeus Beck, Joaquina C Baranda, et al.
Cancer
|
April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer Investigation
|
October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Caio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Translational Medicine Communications
|
April 15, 2025
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Joaquina C Baranda, Ghulam Rehman Mohyuddin, Andrés M Bur, et al.
Clinical and Translational Science
|
June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
JCO Oncology Advances
|
February 7, 2025
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson, et al.
Page
of 1